A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study
Latest Information Update: 28 Aug 2025
At a glance
- Drugs AMT 060 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- Sponsors CSL Behring; uniQure
Most Recent Events
- 07 May 2021 This trial has been Discontinued in Denmark, according to European Clinical Trials Database record.
- 19 Nov 2020 New trial record